{"title":"Paradoxical prognostic impact of severe aortic stenosis following trans-catheter aortic valve implantation","authors":"","doi":"10.1016/j.jjcc.2024.03.010","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div><span>Aortic valve replacement is recommended for patients with “very severe” </span>aortic stenosis (AS), irrespective of symptomatic manifestation. Nonetheless, the prognostic ramifications of “very severe” AS, as opposed to “severe” AS, subsequent to trans-catheter aortic valve implantation (TAVI) remain enigmatic.</div></div><div><h3>Methods</h3><div>We enrolled consecutive patients who received TAVI at our institute between May 2015 and April 2021. We scrutinized the impact of baseline “very severe” AS upon 3-year all-cause death or heart failure hospitalization following TAVI, in comparison to “severe” AS.</div></div><div><h3>Results</h3><div>A total of 239 patients (84.8 ± 5.4 years old, 58 men) were included. Baseline “very severe” AS was observed in 65 (27 %) patients, who exhibited more advanced hypertrophy and higher B-type natriuretic peptide levels compared to those with “severe” AS (<em>p</em> < 0.05 for both). Baseline “very severe” AS was paradoxically associated with higher freedom from the primary endpoint following TAVI compared to those with “severe” AS (<em>p</em> = 0.01).</div></div><div><h3>Conclusions</h3><div>The presence of baseline “very severe” AS was paradoxically associated with improved clinical outcomes subsequent to TAVI, in contrast to the cases of “severe” AS.</div></div>","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":"84 5","pages":"Pages 311-316"},"PeriodicalIF":2.5000,"publicationDate":"2024-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of cardiology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S091450872400056X","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Aortic valve replacement is recommended for patients with “very severe” aortic stenosis (AS), irrespective of symptomatic manifestation. Nonetheless, the prognostic ramifications of “very severe” AS, as opposed to “severe” AS, subsequent to trans-catheter aortic valve implantation (TAVI) remain enigmatic.
Methods
We enrolled consecutive patients who received TAVI at our institute between May 2015 and April 2021. We scrutinized the impact of baseline “very severe” AS upon 3-year all-cause death or heart failure hospitalization following TAVI, in comparison to “severe” AS.
Results
A total of 239 patients (84.8 ± 5.4 years old, 58 men) were included. Baseline “very severe” AS was observed in 65 (27 %) patients, who exhibited more advanced hypertrophy and higher B-type natriuretic peptide levels compared to those with “severe” AS (p < 0.05 for both). Baseline “very severe” AS was paradoxically associated with higher freedom from the primary endpoint following TAVI compared to those with “severe” AS (p = 0.01).
Conclusions
The presence of baseline “very severe” AS was paradoxically associated with improved clinical outcomes subsequent to TAVI, in contrast to the cases of “severe” AS.
期刊介绍:
The official journal of the Japanese College of Cardiology is an international, English language, peer-reviewed journal publishing the latest findings in cardiovascular medicine. Journal of Cardiology (JC) aims to publish the highest-quality material covering original basic and clinical research on all aspects of cardiovascular disease. Topics covered include ischemic heart disease, cardiomyopathy, valvular heart disease, vascular disease, hypertension, arrhythmia, congenital heart disease, pharmacological and non-pharmacological treatment, new diagnostic techniques, and cardiovascular imaging. JC also publishes a selection of review articles, clinical trials, short communications, and important messages and letters to the editor.